NEW YORK – Adaptive Biotechnologies said this week that it has identified a diagnostically useful T cell profile for Lyme disease.
It's an important early step in developing immunoSeq Dx, a single clinical assay that the Seattle-based immune sequencing company intends to be able to use as a diagnostic for infectious disease, autoimmune disease, and cancer.
On a conference call with investors, company officials said they've begun discussions with the US Food and Drug Administration on how to get regulatory approval for their ultimate vision of a multi-faceted test.